Petros Family Wealth LLC Invests $220,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

Petros Family Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 423 shares of the medical research company’s stock, valued at approximately $220,000.

Other hedge funds have also added to or reduced their stakes in the company. Coign Capital Advisors LLC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $619,000. Heritage Trust Co purchased a new position in Thermo Fisher Scientific in the fourth quarter worth about $612,000. Andrew Hill Investment Advisors Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $1,529,000. Kennedy Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 13.5% during the fourth quarter. Kennedy Capital Management LLC now owns 34,372 shares of the medical research company’s stock valued at $17,881,000 after acquiring an additional 4,084 shares in the last quarter. Finally, Scotia Capital Inc. lifted its position in Thermo Fisher Scientific by 57.3% in the 4th quarter. Scotia Capital Inc. now owns 63,585 shares of the medical research company’s stock valued at $33,082,000 after acquiring an additional 23,168 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 9,825 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the transaction, the chief financial officer now owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,900 shares of company stock valued at $13,106,062. Corporate insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Barclays decreased their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research note on Thursday. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Scotiabank boosted their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a report on Monday, February 3rd. Raymond James reaffirmed an “outperform” rating and issued a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Finally, Royal Bank of Canada set a $693.00 price target on Thermo Fisher Scientific in a report on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $647.43.

Thermo Fisher Scientific Stock Up 2.4 %

Shares of TMO stock opened at $437.91 on Friday. The company has a market capitalization of $165.21 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company’s fifty day moving average price is $510.56 and its 200-day moving average price is $539.34. Thermo Fisher Scientific Inc. has a one year low of $409.85 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.